Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 167

1.

Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy.

Jeong SH, Jung JH, Han JH, Kim JH, Choi YW, Lee HW, Kang SY, Hwang YH, Ahn MS, Choi JH, Oh YT, Chun M, Kang S, Park KJ, Hwang SC, Sheen SS.

Lung Cancer. 2010 May;68(2):288-94. doi: 10.1016/j.lungcan.2009.06.003. Epub 2009 Jun 27.

PMID:
19560836
[PubMed - indexed for MEDLINE]
2.

Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy.

Lee HW, Choi YW, Han JH, Kim JH, Jung JH, Jeong SH, Kang SY, Choi JH, Oh YT, Park KJ, Hwang SC, Sheen SS.

Lung Cancer. 2009 Sep;65(3):377-82. doi: 10.1016/j.lungcan.2008.12.005. Epub 2009 Jan 16.

PMID:
19150580
[PubMed - indexed for MEDLINE]
3.

Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced non-small cell lung cancer who received neoadjuvant chemotherapy.

Li J, Li ZN, Yu LC, Bao QL, Wu JR, Shi SB, Li XQ.

Lung Cancer. 2010 Jul;69(1):116-22. doi: 10.1016/j.lungcan.2009.09.013. Epub 2009 Oct 28.

PMID:
19875192
[PubMed - indexed for MEDLINE]
4.

Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer.

Lee HW, Han JH, Kim JH, Lee MH, Jeong SH, Kang SY, Choi JH, Oh YT, Park KJ, Hwang SC, Sheen SS, Lim HY.

Lung Cancer. 2008 Jan;59(1):95-104. Epub 2007 Sep 21.

PMID:
17889401
[PubMed - indexed for MEDLINE]
5.

Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.

Ota S, Ishii G, Goto K, Kubota K, Kim YH, Kojika M, Murata Y, Yamazaki M, Nishiwaki Y, Eguchi K, Ochiai A.

Lung Cancer. 2009 Apr;64(1):98-104. doi: 10.1016/j.lungcan.2008.07.014. Epub 2008 Sep 26.

PMID:
18823676
[PubMed - indexed for MEDLINE]
6.

[Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].

Huang PY, Liang XM, Lin SX, Luo RZ, Hou JH, Zhang L.

Ai Zheng. 2004 Jul;23(7):845-50. Chinese.

PMID:
15248926
[PubMed - indexed for MEDLINE]
7.

The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection.

Kang CH, Jang BG, Kim DW, Chung DH, Kim YT, Jheon S, Sung SW, Kim JH.

Lung Cancer. 2010 Jun;68(3):478-83. doi: 10.1016/j.lungcan.2009.07.004. Epub 2009 Aug 15.

PMID:
19683826
[PubMed - indexed for MEDLINE]
8.

Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.

Ludovini V, Gregorc V, Pistola L, Mihaylova Z, Floriani I, Darwish S, Stracci F, Tofanetti FR, Ferraldeschi M, Di Carlo L, Ragusa M, Daddi G, Tonato M.

Lung Cancer. 2004 Oct;46(1):77-85.

PMID:
15364135
[PubMed - indexed for MEDLINE]
9.
10.

Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer.

Apolinario RM, van der Valk P, de Jong JS, Deville W, van Ark-Otte J, Dingemans AM, van Mourik JC, Postmus PE, Pinedo HM, Giaccone G.

J Clin Oncol. 1997 Jun;15(6):2456-66.

PMID:
9196162
[PubMed - indexed for MEDLINE]
11.

ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.

Hwang IG, Ahn MJ, Park BB, Ahn YC, Han J, Lee S, Kim J, Shim YM, Ahn JS, Park K.

Cancer. 2008 Sep 15;113(6):1379-86. doi: 10.1002/cncr.23693.

PMID:
18623378
[PubMed - indexed for MEDLINE]
Free Article
12.

Low expression of Bax predicts poor prognosis in patients with locally advanced esophageal cancer treated with definitive chemoradiotherapy.

Kang SY, Han JH, Lee KJ, Choi JH, Park JI, Kim HI, Lee HW, Jang JH, Park JS, Kim HC, Kang S, Oh YT, Chun M, Kim JH, Sheen SS, Lim HY.

Clin Cancer Res. 2007 Jul 15;13(14):4146-53.

PMID:
17634542
[PubMed - indexed for MEDLINE]
Free Article
13.

Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.

Machtay M, Lee JH, Stevenson JP, Shrager JB, Algazy KM, Treat J, Kaiser LR.

J Thorac Cardiovasc Surg. 2004 Jan;127(1):108-13.

PMID:
14752420
[PubMed - indexed for MEDLINE]
14.

Expression of MRP1, BCRP, LRP and ERCC1 as prognostic factors in non-small cell lung cancer patients receiving postoperative cisplatin-based chemotherapy.

Li XQ, Li J, Shi SB, Chen P, Yu LC, Bao QL.

Int J Biol Markers. 2009 Oct-Dec;24(4):230-7.

PMID:
20082278
[PubMed - indexed for MEDLINE]
15.

Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.

Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, Ikeda J, Itoh K, Yamada A, Kage M, Kuwano M, Aizawa H.

Lung Cancer. 2009 Jun;64(3):326-33. doi: 10.1016/j.lungcan.2008.09.002. Epub 2008 Nov 1.

PMID:
18977553
[PubMed - indexed for MEDLINE]
16.

Relevance of p53, bcl-2 and Rb expression on resistance to cisplatin-based chemotherapy in advanced non-small cell lung cancer.

Gregorc V, Ludovini V, Pistola L, Darwish S, Floriani I, Bellezza G, Sidoni A, Cavaliere A, Scheibel M, De Angelis V, Bucciarelli E, Tonato M.

Lung Cancer. 2003 Jan;39(1):41-8.

PMID:
12499093
[PubMed - indexed for MEDLINE]
17.

p53 and bcl-2 expression in locally advanced squamous cell head-neck cancer treated with platinum based chemotherapy and radiotherapy.

Giatromanolaki A, Koukourakis M, Zaramboukas T, Skordalaki A, Arapantoni P, Georgoulias V, Fountzilas G.

Anticancer Res. 1998 Nov-Dec;18(6B):4685-92.

PMID:
9891541
[PubMed - indexed for MEDLINE]
18.

Neoadjuvant etoposide, ifosfamide, and cisplatin followed by concomitant thoracic radiotherapy and continuous cisplatin infusion in stage IIIb non-small cell lung cancer.

Pujol JL, Lafontaine T, Quantin X, Reme-Saumon M, Cupissol D, Khial F, Michel FB.

Chest. 1999 Jan;115(1):144-50.

PMID:
9925076
[PubMed - indexed for MEDLINE]
19.

[Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].

Qian XP, Liu BR, Shi MQ, Liu XZ, Hu WJ, Zou ZY, Wei J.

Zhonghua Zhong Liu Za Zhi. 2009 Jan;31(1):33-7. Chinese.

PMID:
19538866
[PubMed - indexed for MEDLINE]
20.

A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.

Segawa Y, Ueoka H, Kiura K, Kamei H, Tabata M, Sakae K, Hiraki Y, Kawahara S, Eguchi K, Hiraki S, Harada M.

Br J Cancer. 2000 Jan;82(1):104-11.

PMID:
10638975
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk